Theravance Biopharma (TBPH) Set to Release Quarterly Earnings on Tuesday

Theravance Biopharma (NASDAQ:TBPH) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Theravance Biopharma to post earnings of $0.24 per share and revenue of $21.95 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 12:30 PM ET.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. On average, analysts expect Theravance Biopharma to post $1.56 EPS for the current fiscal year and $0.81 EPS for the next fiscal year.

Theravance Biopharma Price Performance

NASDAQ TBPH remained flat at $17.03 during trading on Tuesday. The firm has a market capitalization of $884.18 million, a price-to-earnings ratio of 16.86 and a beta of 0.25. The company has a fifty day moving average price of $17.03 and a two-hundred day moving average price of $16.99. Theravance Biopharma has a 1 year low of $13.08 and a 1 year high of $21.03.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TBPH shares. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their price target for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Finally, BTIG Research dropped coverage on shares of Theravance Biopharma in a report on Thursday, September 24th. They set a “neutral” rating on the stock. Seven analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $19.00.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the transaction, the senior vice president owned 213,476 shares of the company’s stock, valued at approximately $3,635,496.28. This trade represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.65% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on respiratory disorders and other conditions where there is a significant unmet medical need. The company’s research and development activities have historically centered on therapies designed to improve lung function and address chronic respiratory disease.

Its principal marketed product is Yupelri (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD).